Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study

被引：0
|
作者：
Rathkopf, Dana E.
Roubaud, Guilhem
Chi, Kim N.
Efstathiou, Eleni
Attard, Gerhardt
Olmos, David
Small, Eric J.
Saad, Marniza
Castro, Elena
Kim, Won
Wu, Daphne
Bertzos, Kristi
Dibaj, Shiva
Zhang, Jenny
Francis, Peter St. John
Smith, Matthew Raymond
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Inst Bergonie, Dept Med Oncol, Bordeaux, France
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Houston Methodist Hosp, Dept Med Oncol, Houston, TX USA
[5] UCL, London, England
[6] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre, Madrid, Spain
[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[8] Univ Malaya, Fac Med, Dept Clin Oncol, Kuala Lumpur, Malaysia
[9] Univ Hosp Virgen de la Victoria HUVV, Malaga, Spain
[10] Janssen R&D US, Los Angeles, CA USA
[11] Janssen Res & Dev LLC, Los Angeles, CA USA
[12] Janssen Global Commercial Strategy Org, Horsham, PA USA
[13] Janssen Res & Dev LLC, San Diego, CA USA
[14] Johnson&Johnson, Spring House, PA USA
[15] Janssen Res & Dev LLC, Raritan, NJ USA
[16] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[17] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：105 / 105
页数：1
相关论文
共 50 条
  • [1] PATIENT-REPORTED OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND BRCA1/2 MUTATIONS RECEIVING FIRST-LINE NIRAPARIB WITH ABIRATERONE ACETATE PLUS PREDNISONE ( MAGNITUDE STUDY)
    Nguyen, Celine
    Rathkopf, Dana E.
    Chi, Kim N.
    Small, Eric
    Smith, Matthew
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [2] Gene for Gene Analysis in the MAGNITUDE Study of Niraparib (NIRA) and Abiraterone Acetate plus Prednisone (AAP) in Patients (pts) with metastatic castration-resistant Prostate Cancer (mCRPC) and homologous Recombination Repair (HRR) Gene Alterations
    Schlack, K.
    Sandhu, S.
    Attard, G.
    Olmos, D.
    Efstathiou, E.
    Castro, E.
    Rathkopf, D. E.
    Smith, M. R.
    Roubaud, G.
    Small, E. J.
    Pereira de Santana Gomes, A. J.
    Saad, M.
    Tural, D.
    Thomas, S.
    Urtishak, K.
    Gormley, M.
    Mason, G. E.
    Diorio, B.
    Wang, G.
    Lopez-Gitlitz, A.
    Chi, K. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 185 - 186
  • [3] Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
    Sandhu, Shahneen
    Attard, Gerhardt
    Olmos, David
    Efstathiou, Eleni
    Castro, Elena
    Rathkopf, Dana E.
    Smith, Matthew Raymond
    Roubaud, Guilhem
    Small, Eric Jay
    Gomes, Andrea Juliana
    Saad, Marniza
    Tural, Deniz
    Thomas, Shibu
    Urtishak, Karen
    Gormley, Michael
    Mason, Gary
    Diorio, Brooke
    Wang, George C.
    Lopez-Gitlitz, Angela
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE.
    Efstathiou, Eleni
    Smith, Matthew Raymond
    Sandhu, Shahneen
    Attard, Gerhardt
    Saad, Marniza
    Olmos, David
    Castro, Elena
    Roubaud, Guilhem
    Gomes, Andrea Juliana
    Small, Eric Jay
    Rathkopf, Dana E.
    Gurney, Howard
    Jung, Wonho
    Mason, Gary
    Francis, Peter St. John
    Wang, George C.
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela Mennicke
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] Niraparib plus abiraterone acetate plus prednisone (NIRA plus AAP) as first-line treatment in patients with BRCA plus metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study
    Saad, M.
    Chi, K. N.
    Sandhu, S. K.
    Attard, G.
    Ye, D.
    Li, L.
    Jung, W.
    Pang, S-T.
    Francis, P. S. J.
    Li, S.
    Dibaj, S.
    Zhang, J.
    Kim, W.
    Lopez-Gitlitz, A.
    Wu, D.
    Singh, A.
    De Vries, R.
    Zhang, L.
    Lee, J. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1573 - S1574
  • [6] Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate plus prednisone (AAP) or enzalutamide (ENZ).
    Vuillemin, Antoine Thiery
    Poulsen, Mads Hvid
    Dourthe, Louis-Marie
    Trepiakas, Redas
    Lagneau, Edouard
    Pintus, Elias Pasquale
    Beal-Ardisson, Dominique
    Birtle, Alison Jane
    Ploussard, Guillaume
    Besson, Herve
    Lukac, Martin
    Robinson, Paul
    Reid, Alison Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] NIRAPARIB WITH ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM THE PHASE 2 QUEST STUDY
    Chi, Kim
    Fleshner, Neil
    Chiuri, Vincenzo Emanuele
    Van Bruwaene, Siska
    Hafron, Jason
    McNeel, Douglas G.
    De Porre, Peter
    Maul, R. Scott
    Daksh, Mahesh
    Zhong, Xiaogang
    Mason, Gary E.
    Tutrone, Ronald
    JOURNAL OF UROLOGY, 2022, 207 (05): : E456 - E457
  • [8] Health-related quality of life (HRQoL) and pain in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.
    Chi, Kim N.
    Rathkopf, Dana E.
    Smith, Matthew Raymond
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric Jay
    Gomes, Andrea Juliana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary
    del Corral, Adam
    Wang, George C.
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela Mennicke
    Sandhu, Shahneen Kaur
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [10] Niraparib with abiraterone acetate and prednisone (NIRA plus AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR plus ) gene alterations: Asian subgroup analysis of the MAGNITUDE study
    Saad, M. Binti
    Chi, K. N.
    Jung, W.
    Pang, S-T.
    Attard, G.
    Sandhu, S. K.
    Mason, G. E.
    del Corral, A.
    Wang, G.
    Wu, D.
    Diorio, B.
    Lopez-Gitlitz, A.
    Lee, J. Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1496 - S1496
12345